Skip to menu Skip to content Skip to footer

2022

Journal Article

Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience

Levy, Julia, Farag, Fady and Cole, John (2022). Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. Breast Cancer Research and Treatment, 196 (1), 207-213. doi: 10.1007/s10549-022-06735-9

Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience

2017

Journal Article

Endocrine therapy for early breast cancer: Updated review

Tremont, Alexander, Lu, Jonathan and Cole, John T. (2017). Endocrine therapy for early breast cancer: Updated review. Ochsner Journal, 17 (4), 405-411. doi: 10.1043/TOJ-17-0036

Endocrine therapy for early breast cancer: Updated review

2015

Journal Article

Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy

Jahangir, Eiman, Shah, Sangeeta, Shum, Kelly, Baxter, Caitlin, Fitzpatrick, Jill D., Cole, John, Gilliland, Yvonne and Polin, Nichole M. (2015). Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy. Southern Medical Journal, 108 (2), 71-78. doi: 10.14423/SMJ.0000000000000232

Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy

2013

Journal Article

Cancer stem cell and stromal microenvironment

Li, Li, Cole, John and Margolin, David A. (2013). Cancer stem cell and stromal microenvironment. Ochsner Journal, 13 (1), 109-118.

Cancer stem cell and stromal microenvironment

2012

Journal Article

A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential

Lee, Chung-Gi, Das, Bikul, Lin, Tara L., Grimes, Chelsea, Zhang, Xin, Lavezzi, Tracey, Huang, Li, Cole, John, Yau, Lillian and Li, Li (2012). A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. British Journal of Haematology, 158 (1), 79-90. doi: 10.1111/j.1365-2141.2012.09123.x

A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential

2010

Journal Article

Pegylated arginase I: a potential therapeutic approach in T-ALL

Hernandez, Claudia P., Morrow, Kevin, Lopez-Barcons, Lluis A., Zabaleta, Jovanny, Sierra, Rosa, Velasco, Cruz, Cole, John and Rodriguez, Paulo C. (2010). Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood, 115 (25), 5214-5221. doi: 10.1182/blood-2009-12-258822

Pegylated arginase I: a potential therapeutic approach in T-ALL

2007

Journal Article

Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics

Prakash, Om, Bardot, Stephen F. and Cole, John T. (2007). Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics. Ochsner Journal, 7 (2), 61-64.

Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics

2005

Journal Article

A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932

Perez, Edith A., Suman, Vera J., Fitch, Tom R., Mailliard, James A., Ingle, James N., Cole, John T., Veeder, Michael H., Flynn, Patrick J., Walsh, Daniel J. and Addo, Ferdinand K. (2005). A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology, 69 (2), 117-121. doi: 10.1159/000087813

A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932

2004

Journal Article

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer

Le Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G. ... Wedel, H. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 (4), 351-360. doi: 10.1056/NEJMoa031644

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer

2001

Journal Article

A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma

Buckner, J. C., Schomberg, P. J., McGinnis, W. L., Cascino, T. L., Scheithauer, B. W., O'Fallon, J. R., Morton, R. F., Kuross, S. A., Mailliard, J. A., Hatfield, A. K., Cole, J. T., Steen, P. D. and Bernath, A. M. (2001). A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma. Cancer, 92 (2), 420-433. doi: 10.1002/1097-0142(20010715)92:23.0.CO;2-3

A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma

1995

Journal Article

Sepsis due to coryneform group A-4 in an immunocompromised host

Bizette, G. A., Kemmerly, S. A., Cole, J. T., Bradford, H. B. and Peltier, B. H. (1995). Sepsis due to coryneform group A-4 in an immunocompromised host. Clinical Infectious Diseases, 21 (5), 1334-1336. doi: 10.1093/clinids/21.5.1334

Sepsis due to coryneform group A-4 in an immunocompromised host

1993

Journal Article

SPLENECTOMY IN THE HIV-INFECTED PATIENT - REPLY

COLE, JT and FLAUM, MA (1993). SPLENECTOMY IN THE HIV-INFECTED PATIENT - REPLY. Southern Medical Journal, 86 (8), 980-980. doi: 10.1097/00007611-199308000-00032

SPLENECTOMY IN THE HIV-INFECTED PATIENT - REPLY

1992

Journal Article

Postsplenectomy infections

Cole, J. T. and Flaum, M. A. (1992). Postsplenectomy infections. Southern Medical Journal, 85 (12), 1220-1226. doi: 10.1097/00007611-199212000-00014

Postsplenectomy infections

1991

Journal Article

A Phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer

Bhalla, K., Birkhofer, M., Bhalla, M., Lutzky, J., Hindenburg, A., Cole, J. and Ince, C. (1991). A Phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. American Journal of Clinical Oncology - Cancer Clinical Trials, 14 (6), 509-513. doi: 10.1097/00000421-199112000-00009

A Phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer

1990

Journal Article

Acute myelomonocytic leukemia presenting as a benign-appearing cutaneous eruption

Horlick, Howard P., Silvers, David N., Knobler, Elizabeth H. and Cole, John T. (1990). Acute myelomonocytic leukemia presenting as a benign-appearing cutaneous eruption. Archives of Dermatology, 126 (5), 653-656. doi: 10.1001/archderm.126.5.653

Acute myelomonocytic leukemia presenting as a benign-appearing cutaneous eruption

1990

Journal Article

The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine

Bhalla, K. N., Li, G. R., Grant, S., Cole, J. T., Maclaughlin, W. W. and Volsky, D. J. (1990). The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine. Aids, 4 (5), 427-431. doi: 10.1097/00002030-199005000-00008

The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine

1989

Journal Article

2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity

Bhalla, K., Birkhofer, M., Li, G. R., Grant, S., Maclaughlin, W., Cole, J., Graham, G. and Volsky, D. J. (1989). 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood, 74 (6), 1923-1928.

2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity

1988

Journal Article

Phase I clinical and pharmacologic study of deoxycytidine

Bhalla, K., Birkhofer, M., Grant, S., Baker, M., Maclaughlin, W., Cole, J. and Graham, G. (1988). Phase I clinical and pharmacologic study of deoxycytidine. Leukemia, 2 (10), 709-710.

Phase I clinical and pharmacologic study of deoxycytidine

1987

Journal Article

Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells

Bhalla, K., Cole, J., Maclaughlin, W., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1987). Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells. Leukemia, 1 (12), 814-819.

Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells

1987

Journal Article

Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity

Bhalla, K., Maclaughlin, W., Cole, J., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1987). Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood, 70 (2), 568-571.

Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity